GeoVax Provides Update on its Zika Vaccine Development

Biotech Investing

GeoVax Labs announced it is providing an updated presentation of results from studies of GeoVax’s NS-1 based Zika vaccine during the Vaccine Congress conference.

GeoVax Labs (OTCQB:GOVX) announced it is providing an updated presentation of results from studies of GeoVax’s NS-1 based Zika vaccine during the Vaccine Congress conference.
As quoted in the press release:

Dr. Guirakhoo will deliver the talk, entitled “Development of a Novel Vaccine for Zika,” today during the 11^th Vaccine Congress in San Diego, CA.
Dr. Guirakhoo is presenting research showing that a single intramuscular dose of GeoVax’s Zika vaccine gave 100% protection in normal mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is i) the only Zika vaccine in development which is based on the NS1 protein, and ii) the first report of single-dose full protection against ZIKV using an immunocompetent lethal mouse challenge model.

Click here to read the full press release.

Source: www.marketwired.com

congress geovax geovax labs mice vaccine zika zika virus Biotech Investing